When the failure to satisfy CGMP ends in the distribution of a drug that does not supply the gain as labeled since, for instance, it has too small active ingredient, the corporation may perhaps subsequently remember that product or service.S. market, either right or indirectly by incorporation into finished dosages created in China or other aspects